



BRAZILIAN PATENT ISSUED PROTECTING BARD1 TECHNOLOGY FOR LUNG AND COLORECTAL CANCER

- Brazilian patent granted covering use of BARD1 isoforms in lung and colorectal cancer
- Protects a BARD1 autoantibody test for detection of lung or colorectal cancer

Melbourne, Australia, 23 February 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that Brazilian Patent 112013003506 titled 'BARD1 isoforms in lung and colorectal cancer and use thereof' was issued by the National Institute of Industrial Property (INPI).

The issued BR 112013003506 has claims directed towards the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for discriminating lung cancer and colorectal cancer in body fluids. The patent application was filed by Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011 and is due to expire on 8 February 2032. INOVIQ (via its fully owned subsidiary BARD1AG SA) has an exclusive global license to the commercial rights to this intellectual property from UNIGE/HUG.

CEO Dr Leeanne Hinch said: "There is an important unmet medical need for non-invasive, accurate and reliable tests for earlier detection of lung cancer to improve health outcomes. This patent provides IP protection for a potential BARD1 autoantibody test for lung cancer in Brazil."

This BARD1 patent family now has thirteen granted patents enforcing protection in Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Singapore and the USA.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leeanne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.